Modeling budgetary impact for decision makers

    loading  Checking for direct PDF access through Ovid


The budgetary Implications of using 5-HT3 receptor antagonists In the management of patients with chemotherapy- Induced emesls Is discussed. It was shown that treatment with 5-HT3 receptor antagonists In the acute phase of emesls resulted In relatively little additional cost when Introduced Into a normal management pattern of emesls control, and therefore seems Justifiable. However, In delayed emesls there Is a much more substantial budgetary Impact with no proven clinical benefit, and therefore treatment does not appear to be appropriate In this situation.

Related Topics

    loading  Loading Related Articles